Genmab A/S Mutual Funds

Health Care & Life Sciences » Biotechnology | Genmab A/S

Genmab A/S | Mutual Funds

Mutual Funds that own Genmab A/S

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Vanguard International Growth Fund

2,594,661

4.22%

1.2%

06/30/2018

Vanguard Health Care Fund

1,737,968

2.83%

314,453

0.6%

06/30/2018

ATP Group Portfolio

1,373,692

2.24%

-300,335

0.17%

12/31/2017

Vanguard Total International Stock Index Fund

788,570

1.28%

12,992

0.04%

07/31/2018

Government Pension Fund - Global (The)

763,381

1.24%

-147,619

0.02%

12/31/2017

Artisan International Fund

600,262

0.98%

205,622

0.76%

06/30/2018

Oppenheimer Global Opportunities Fund

600,000

0.98%

1.11%

03/31/2018

Artisan Mid Cap Fund

524,532

0.85%

-1,743

1.37%

06/30/2018

Artisan Global Opportunities Fund

425,260

0.69%

-76,544

2.24%

06/30/2018

Artisan Global Opportunity Trust

415,352

0.68%

-51,050

2.25%

06/30/2018

About Genmab A/S

View Profile

Address	Kalvebod Brygge 43 Copenhagen CR 1560 Denmark
Employees	-
Website	http://www.genmab.com
Updated	07/08/2019
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer. Its antibody product, Arzerra used in the treatment of chronic lymphocytic leukemia indications; and DARZALEX.